Breaking News Instant updates and real-time market news.

ICPT

Intercept

$70.79

0.68 (0.97%)

07:04
04/13/18
04/13
07:04
04/13/18
07:04

Intercept announces data from liver biopsy substudy of POISE Phase 3 trial

Intercept Pharmaceuticals announced clinical data from a liver biopsy-based substudy from the POISE Phase 3 trial suggesting that long-term OCA treatment in patients with PBC was associated with reversal or stabilization of fibrosis and cirrhosis. The data are being presented at the International Liver Congress 2018, the 53rd Annual Meeting of the European Association for the Study of the Liver, in Paris, France, from April 11-15, 2018. OCA is not currently indicated for the reversal of fibrosis or cirrhosis in patients with PBC. Prior longitudinal biopsy studies have shown that patients who are not treated with, or have an inadequate response to, ursodeoxycholic acid, the current standard of care, are at significantly higher risk of fibrosis progression, liver failure, transplant and death. Liver biopsy is not the standard of care in PBC and difficult to obtain in clinical trials. In this voluntary substudy of the POISE Phase 3 trial, paired biopsies adequate for analysis were obtained for 13 patients, all of whom had liver fibrosis or cirrhosis at baseline. After three years of treatment with OCA, the majority of patients improved or maintained histological fibrosis stage, while two patients experienced one stage progression. Of the four patients with cirrhosis at baseline, all showed reversal by at least one stage, and three improved to fibrosis without cirrhosis. Pruritus is the most common symptom in patients with PBC and was also the most common adverse event in the POISE Phase 3 substudy. Nine patients experienced pruritus in the substudy, an incidence consistent with the rate observed in the broader study population. A total of five serious adverse events in five patients were reported. All serious adverse events were considered unlikely to be related, or not related, to OCA. A separate poster, "Durable Response in the Markers of Cholestasis through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis," presented at the International Liver Congress provided additional results from the open-label extension of the POISE trial. Sustained improvements in ALP were observed through three years of OCA therapy, with similar improvements seen for GGT, ALT and AST. Mean total bilirubin remained below baseline throughout the three-year open-label period. The most common adverse event observed with OCA therapy was pruritus, resulting in the discontinuation of seven patients during the open-label extension treatment phase. An additional poster, "Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of POISE, 201, and 202," assessed changes in total bilirubin observed in the POISE Phase 3 trial and two Phase 2 trials. The analysis, which included patients with total bilirubin greater than or equal to0.67 times the upper limit of normal at baseline, found that total bilirubin increased after 12 months of placebo treatment and decreased after 12 months of treatment with OCA. In the double-blind phase of POISE, 14% of placebo-treated and 78% of OCA-treated patients with abnormal total bilirubin at baseline attained normal levels after 12 months. Further, of 10 placebo-treated and 20 OCA-treated patients with normal total bilirubin at baseline, 60% of placebo-treated and 15% of OCA-treated patients worsened to abnormal total bilirubin after 12 months. Per EASL clinical guidelines, increasing bilirubin levels - even within the normal range - indicate progressive disease and are strongly associated with adverse clinical outcomes.

  • 13

    Apr

  • 20

    Apr

  • 08

    May

  • 21

    May

ICPT Intercept
$70.79

0.68 (0.97%)

03/28/18
LEER
03/28/18
NO CHANGE
Target $16
LEER
Outperform
More differentiating data at EASL can continue CymaBay momentum, says Leerink
Leerink analyst Joseph Schwartz expects a 6-month Phase 2 study update for CymaBay's (CBAY) seladelpar in primary biliary cholangitis to be reported at the International Liver Congress. The analyst notes CymaBay stock has enjoyed strong momentum since the preliminary 12-week data and he remains optimistic that seladelpar's profile will continue to look differentiated from Intercept's (ICPT) Ocaliva when it comes to safety/tolerability and efficacy in the second-line PBC treatment setting. The analyst reiterates an Outperform rating and $16 price target on CymaBay's shares.
02/13/18
WELS
02/13/18
NO CHANGE
Target $57
WELS
Market Perform
Intercept price target lowered to $57 from $62 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Intercept to $57 from $62 following his most recent review of the FDA AERS Safety Database for marketed bile acid analog OCALIVA, and significant increase in patient deaths in Q4. While Intercept has highlighted an independent safety review of post-marketing safety events cited in a September, 2017 FDA Drug Safety Communication, the analyst believes that significant increase in patient deaths in Q4 is concerning and the rate is above that predicted for the approved OCALIVA patient population by his estimate. Birchenough reiterates a Market Perform rating on the shares.
02/12/18
DBAB
02/12/18
NO CHANGE
Target $103
DBAB
Buy
Intercept study initiation a positive, says Deutsche Bank
Deutsche Bank analyst Navin Jacob views the initiation of the Reverse NASH trial is a positive for Intercept Pharmaceuticals, saying it "puts to rest any lingering bear arguments that OCA is not safe." The trial, if successful, presents potential upside to numbers, Jacob tells investors in a research note. He keeps a Buy rating on the shares with a $103 price target.
02/07/18
GSCO
02/07/18
DOWNGRADE
Target $45
GSCO
Sell
Intercept downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.

TODAY'S FREE FLY STORIES

BA

Boeing

$374.04

-0.98 (-0.26%)

21:05
04/23/19
04/23
21:05
04/23/19
21:05
Periodicals
Boeing calls for FAA ungrounding of 737 MAX aircraft in May, Reuters says »

Boeing has communicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    Apr

  • 29

    May

  • 05

    Jun

SPY

SPDR S&P 500 ETF Trust

$292.86

2.56 (0.88%)

, SPX

S&P 500

$0.00

(0.00%)

20:54
04/23/19
04/23
20:54
04/23/19
20:54
Periodicals
Lighthizer, Mnuchin to hold trade talks in China on April 30th, Bloomberg says »

The report also notes…

SPY

SPDR S&P 500 ETF Trust

$292.86

2.56 (0.88%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHT

DHT Holdings

$5.17

0.075 (1.47%)

20:46
04/23/19
04/23
20:46
04/23/19
20:46
Upgrade
DHT Holdings rating change at Evercore ISI »

DHT Holdings upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLL

Piedmont Lithium

$12.98

-0.24 (-1.82%)

20:45
04/23/19
04/23
20:45
04/23/19
20:45
Hot Stocks
Piedmont Lithium announces Mineral Resource estimate of 2.8MT at Central »

Piedmont Lithium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.11

0.03 (0.09%)

, BA

Boeing

$374.04

-0.98 (-0.26%)

20:25
04/23/19
04/23
20:25
04/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

T

AT&T

$32.11

0.03 (0.09%)

BA

Boeing

$374.04

-0.98 (-0.26%)

TMO

Thermo Fisher

$263.74

4.68 (1.81%)

CAT

Caterpillar

$142.08

-0.28 (-0.20%)

ANTM

Anthem

$250.75

6.71 (2.75%)

NSC

Norfolk Southern

$201.68

0.15 (0.07%)

GD

General Dynamics

$182.33

5.27 (2.98%)

NOC

Northrop Grumman

$292.59

9.73 (3.44%)

BSX

Boston Scientific

$35.88

0.95 (2.72%)

BIIB

Biogen

$229.89

1.15 (0.50%)

SIRI

Sirius XM

$6.14

0.03 (0.49%)

SWK

Stanley Black & Decker

$147.37

1.89 (1.30%)

DPZ

Domino's Pizza

$270.25

4.19 (1.57%)

KNX

Knight-Swift

$35.01

0.295 (0.85%)

OC

Owens Corning

$55.60

1.24 (2.28%)

GNTX

Gentex

$22.09

0.23 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 26

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 18

    May

  • 18

    May

  • 20

    May

  • 20

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

  • 26

    Jun

  • 13

    Nov

  • 02

    Dec

T

AT&T

$32.11

0.03 (0.09%)

20:09
04/23/19
04/23
20:09
04/23/19
20:09
Hot Stocks
AT&T's WarnerMedia to sell 30 Hudson Yards for ~$2.2B »

WarnerMedia has signed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 18

    May

  • 20

    May

BSX

Boston Scientific

$35.88

0.95 (2.72%)

20:07
04/23/19
04/23
20:07
04/23/19
20:07
Recommendations
Boston Scientific analyst commentary at Piper Jaffray »

Boston Scientific Lotus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 18

    May

  • 20

    May

  • 29

    May

  • 26

    Jun

  • 13

    Nov

FFHL

Fuwei Films

$2.66

0.05 (1.92%)

19:16
04/23/19
04/23
19:16
04/23/19
19:16
Hot Stocks
Fuwei Films delays reporting Q4 results »

Fuwei Films announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWE

NorthWestern

$68.06

0.46 (0.68%)

19:12
04/23/19
04/23
19:12
04/23/19
19:12
Earnings
NorthWestern reports Q1 adjusted EPS $1.23, consensus $1.18 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

MNOV

MediciNova

$10.68

0.77 (7.77%)

19:03
04/23/19
04/23
19:03
04/23/19
19:03
Hot Stocks
MediciNova gets Notice of Allowance from U.S. PTC for MN-166 in glioblastoma »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

MANH

Manhattan Associates

$61.13

0.96 (1.60%)

, CSL

Carlisle

$128.57

1.94 (1.53%)

18:58
04/23/19
04/23
18:58
04/23/19
18:58
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MANH

Manhattan Associates

$61.13

0.96 (1.60%)

CSL

Carlisle

$128.57

1.94 (1.53%)

TER

Teradyne

$44.60

-0.26 (-0.58%)

EBAY

eBay

$36.66

0.51 (1.41%)

SNAP

Snap

$11.99

0.46 (3.99%)

SIX

Six Flags

$52.39

0.8 (1.55%)

NAVI

Navient

$12.45

0.38 (3.15%)

BSX

Boston Scientific

$35.88

0.95 (2.72%)

ABBV

AbbVie

$78.65

0.55 (0.70%)

IRBT

iRobot

$130.42

1.71 (1.33%)

SPN

Superior Energy

$4.97

-0.02 (-0.40%)

RHI

Robert Half

$68.83

1.46 (2.17%)

TSS

TSYS

$102.25

1.46 (1.45%)

SYK

Stryker

$186.95

4.905 (2.69%)

EW

Edwards Lifesciences

$180.89

2.64 (1.48%)

TXN

Texas Instruments

$116.37

1.43 (1.24%)

AMTD

TD Ameritrade

$54.28

0.61 (1.14%)

BURL

Burlington Stores

$161.96

1.76 (1.10%)

CP

Canadian Pacific

$219.33

0.215 (0.10%)

LRN

K12

$36.23

0.805 (2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 28

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 01

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 13

    May

  • 14

    May

  • 14

    May

  • 18

    May

  • 20

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 05

    Jun

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 13

    Nov

GE

General Electric

$9.34

0.02 (0.21%)

18:55
04/23/19
04/23
18:55
04/23/19
18:55
Hot Stocks
DOJ says ex-GE engineer, Chinese man charged with theft of GE trade secrets »

The U.S. Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 08

    May

  • 29

    May

  • 05

    Jun

HAS

Hasbro

$100.34

12.32 (14.00%)

18:23
04/23/19
04/23
18:23
04/23/19
18:23
Hot Stocks
Hasbro CEO: We expect to return to profitable growth this year »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 16

    May

  • 29

    May

ABBV

AbbVie

$78.65

0.55 (0.70%)

18:21
04/23/19
04/23
18:21
04/23/19
18:21
Hot Stocks
AbbVie says FDA approves SKYRIZI »

AbbVie announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 28

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 18

    May

  • 31

    May

  • 05

    Jun

TSS

TSYS

$102.25

1.46 (1.45%)

18:19
04/23/19
04/23
18:19
04/23/19
18:19
Earnings
TSYS backs FY19 EPS view $4.75-$4.90, consensus $4.86 »

Backs FY19 total revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 02

    May

HCC

Warrior Met Coal

$31.78

1.21 (3.96%)

18:16
04/23/19
04/23
18:16
04/23/19
18:16
Hot Stocks
Warrior Met Coal declares $4.41 special cash dividend »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 01

    May

LBTYA

Liberty Global

$27.28

-0.01 (-0.04%)

18:15
04/23/19
04/23
18:15
04/23/19
18:15
Hot Stocks
Liberty Global names Lutz Shuler as Virgin Media CEO »

Liberty Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

VMI

Valmont

$131.14

-1.17 (-0.88%)

18:09
04/23/19
04/23
18:09
04/23/19
18:09
General news
Valmont reaffirms FY19 revenue view up 7%-8% »

Reaffism FY19 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    Apr

VMI

Valmont

$131.14

-1.17 (-0.88%)

18:08
04/23/19
04/23
18:08
04/23/19
18:08
Earnings
Valmont narrows FY19 EPS view to $8.30-$8.90 from $8.10-$8.90 »

Consensus is for FY19 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    Apr

VMI

Valmont

$131.14

-1.17 (-0.88%)

18:07
04/23/19
04/23
18:07
04/23/19
18:07
Earnings
Valmont reports Q1 EPS $1.84 ex-items, consensus $1.74 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    Apr

HNHPF

Hon Hai Precision

$0.00

(0.00%)

18:06
04/23/19
04/23
18:06
04/23/19
18:06
Periodicals
Foxconn, Wisconsin renegotiating LCD plant contract, CNBC reports »

Wisconsin Governor Tony…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$35.88

0.95 (2.72%)

17:47
04/23/19
04/23
17:47
04/23/19
17:47
Hot Stocks
Breaking Hot Stocks news story on Boston Scientific »

Boston Scientific up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 18

    May

  • 20

    May

  • 29

    May

  • 26

    Jun

  • 13

    Nov

TPL

Texas Pacific Land Trust

$896.00

0.19 (0.02%)

17:45
04/23/19
04/23
17:45
04/23/19
17:45
Hot Stocks
Texas Pacific Land Trust says trustee nominee Eric Oliver should be disqualified »

Texas Pacific Land Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$120.11

-0.26 (-0.22%)

17:41
04/23/19
04/23
17:41
04/23/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 749.63MT from 751.68MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$11.99

0.46 (3.99%)

17:39
04/23/19
04/23
17:39
04/23/19
17:39
Hot Stocks
Snap CEO says 'definitely excited about what we're seeing' with new Android app »

Says there is "a lot…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.